Dentsply Sirona Inc. · NASDAQ:XRAY
Dentsply Sirona — Q3 2026 Earnings Presentation
20 slides from Dentsply Sirona's earnings presentation, Nov 5, 2026
Slide 1: Third Quarter 2026 Earnings Conference Call
November 5, 2026 Third Quarter 2026 Earnings Conference Call
Slide 2: Forward-Looking Statements and Associated Risks
Forward-Looking Statements and Associated Risks All statements in this Presentation that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause ac
Slide 3: Key Developments
Key Developments Building positive momentum in the U.S. through Return- to-Growth Action Plan Record quarterly sales for Wellspect Healthcare; completed U.S. launch of Wellspect SurityTM portfolio Accelerating execution of the redesigned North American Clinical Education program with 6x spend increa
Slide 4: Established North American Distributor Network
Established North American Distributor Network New Agreements Simplifying Broadening Access to Operating Model Capital Equipment Seven new distribution agreements signed YTD Expanding commercial reach across North Simplified incentive structure and inventory America and key regional markets mo
Slide 5: U.S. Sales Force Investment: Signs of Progress
U.S. Sales Force Investment: Signs of Progress Stronger field coverage and capabilities are supporting early commercial gains STABILIZING COVERAGE BUILDING CAPABILITIES EARLY MIS RESULTS Recruit & Retain 100% certified Double-digit Improved significantly; Premium implant sales force U.S. MIS sales g
Slide 6: We provide the education our customers need to adopt and use our solutions
We provide the education our customers need to adopt and use our solutions with confidence Executing a step-change in clinical education investment in North America Scaling hands-on training, digital access and clinician engagement across the dental community >160 Endo courses in H2 6× >60% increase
Slide 7: Early Signs of Progress Across Key Product Lines
Early Signs of Progress Across Key Product Lines Sales training and clinical education are supporting early gains in adoption and sales SALES MOMENTUM ADOPTION & CUSTOMER ENGAGEMENT ENDODONTICS Reciproc Blue growth More repeat use Continued year-over-year growth, Reorder rates improved consistently
Slide 8: Achieved Record Wellspect Sales Powered by Innovation
Achieved Record Wellspect Sales Powered by Innovation Completed Launch of Wellspect SurityTM Portfolio in the U.S. Female External Male External Urinary Management Medicare Catheter Catheter System Reimbursement Surity female external Surity male external Surity Urinary Surity portfolio, may
Slide 9: Transformation Office Shifting from Stabilization to Value Creation
Transformation Office Shifting from Stabilization to Value Creation Stabilizing the Business Scale the Model Operating Mechanism ~$120M ✓ Quote-to-Cash Transformation Office, 01 CUSTOMER governance and Simplify pricing, ordering, EXPERIENCE accountability fulfillment, billing and collections savings
Slide 10: Third Quarter 2026 Financial Summary
Third Quarter 2026 Financial Summary 10
Slide 11: Third Quarter 2026 Financial Summary
Third Quarter 2026 Financial Summary Commentary Q3 2026 Q3 2025 YoY Net sales (7.6%) YoY Declines in EDS, CTS, and OIS, partially Net Sales $836M $904M (7.6%) offset by Wellspect Constant currency revenue down (7.0%) Constant (7.0%) Currency Adj. EBITDA margin 17.3%, (110) bps YoY Lower vo
Slide 12: Third Quarter 2026 Segment Results
Third Quarter 2026 Segment Results As Constant Net Sales Commentary Reported Currency CAD/CAM: Lower volumes in Americas driven by the planned shift Connected in distributor inventory model Technology Solutions $230M (11.0%) (10.1%) Equipment & Instruments: Lower volumes of Imaging products (CTS
Slide 13: Updated 2026 Outlook
Updated 2026 Outlook* Prior Outlook Current Outlook Net Sales $3.5B to $3.6B $3.5B Adjusted EPS $1.40 to $1.50 $1.20 to $1.30 13 *Actual results may differ materially due to a number of factors and risks, including those described in the Company’s filings with the SEC Note: The benefits of refunds f
Slide 14: Appendix
Appendix 14
Slide 15: Non-GAAP Financial Measures Definitions
Non-GAAP Financial Measures Definitions Constant Currency Adjusted Gross Profit and Margin Reported net sales adjusted for the impact of foreign currency changes, which is Gross profit excluding the impact of any of the above adjustments that affect either calculated by translating current period ne
Slide 16: Net Sales as Reported and in Constant Currency
Net Sales as Reported and in Constant Currency (unaudited) 16
Slide 17: Reconciliation of Non-GAAP Financial Measures: Statements of Operations
Reconciliation of Non-GAAP Financial Measures Condensed Consolidated Statements of Operations (in millions, except per-share amounts) (unaudited) 17
Slide 18: Reconciliation of Non-GAAP Financial Measures: Statements of Operations
Reconciliation of Non-GAAP Financial Measures Condensed Consolidated Statements of Operations (in millions, except per-share amounts) (unaudited) 18
Slide 19: Reconciliation of Non-GAAP Financial Measures: Adjusted EBITDA
Reconciliation of Non-GAAP Financial Measures Adjusted EBITDA (in millions) (unaudited) 19
Slide 20: 20
20